{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:00Z","timestamp":1786979940198,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,2,23]],"date-time":"2005-02-23T00:00:00Z","timestamp":1109116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1007\/s00280-004-0900-4","type":"journal-article","created":{"date-parts":[[2005,2,22]],"date-time":"2005-02-22T10:42:30Z","timestamp":1109068950000},"page":"488-496","source":"Crossref","is-referenced-by-count":45,"title":["Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma"],"prefix":"10.1007","volume":"55","author":[{"given":"M.","family":"Joerger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. L.","family":"Meenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,2,23]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00001622-200003000-00013","volume":"12","author":"RT Mitsuyasu","year":"2000","unstructured":"Mitsuyasu RT (2000) Update on the pathogenesis and treatment of Kaposi sarcoma. Curr Opin Oncol 12:174?180","journal-title":"Curr Opin Oncol"},{"key":"CR2","first-page":"1","volume":"12","author":"JH Roenn Von","year":"1998","unstructured":"Von Roenn JH, Krown SE (1998) Management of AIDS-associated Kaposi?s sarcoma: a multidisciplinary perspective. Oncology (Huntingt) 12:1?24","journal-title":"Oncology (Huntingt)"},{"key":"CR3","first-page":"93","volume-title":"A clinician?s guide to chemotherapy pharmacokinetics and pharmacodynamics","author":"J Robert","year":"1998","unstructured":"Robert J (1998) Anthracyclines. In: Grochow LB, Ames MM (eds) A clinician?s guide to chemotherapy pharmacokinetics and pharmacodynamics. Williams&Wilkins, Baltimore, pp 93?173"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02086146","volume":"8","author":"J Bouma","year":"1986","unstructured":"Bouma J, Beijnen JH, Bult A, Underberg WJ (1986) Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties. Pharm Weekbl Sci 8:109?133","journal-title":"Pharm Weekbl Sci"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0277-5379(86)90112-4","volume":"22","author":"J Cummings","year":"1986","unstructured":"Cummings J, Merry S, Willmott N (1986) Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS). Eur J Cancer Clin Oncol 22:451?460","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s002800050999","volume":"44","author":"A Andersen","year":"1999","unstructured":"Andersen A, Holte H, Slordal L (1999) Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol 44:422?426","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/clpt.1993.69","volume":"53","author":"SC Piscitelli","year":"1993","unstructured":"Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53:555?561","journal-title":"Clin Pharmacol Ther"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.1988.6.3.517","volume":"6","author":"K Mross","year":"1988","unstructured":"Mross K, Maessen P, van der Vijgh WJF, Gall H, Boven E, Pinedo HM (1988) Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6:517?526","journal-title":"J Clin Oncol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0277-5379(89)90007-2","volume":"25","author":"M Frenay","year":"1989","unstructured":"Frenay M, Milano G, Renee N, Pons D, Khater R, Francois E, Thyss A, Namer M (1989) Pharmacokinetics of weekly low dose doxorubicin. Eur J Cancer Clin Oncol 25:191?195","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/clpt.1987.92","volume":"41","author":"PA Speth","year":"1987","unstructured":"Speth PA, Linssen PC, Holdrinet RS, Haanen C (1987) Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin Pharmacol Ther 41:661?665","journal-title":"Clin Pharmacol Ther"},{"key":"CR11","first-page":"219","volume":"17","author":"J Robert","year":"1993","unstructured":"Robert J, Gianni L (1993) Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 17:219?252","journal-title":"Cancer Surv"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00609693","volume":"28","author":"S Eksborg","year":"1985","unstructured":"Eksborg S, Strandler HS, Edsmyr F, Naslund I, Tahvanainen P (1985) Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol 28:205?212","journal-title":"Eur J Clin Pharmacol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1021\/tx000013q","volume":"13","author":"S Licata","year":"2000","unstructured":"Licata S, Saponiero A, Mordente A, Minotti G (2000) Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 13:414?420","journal-title":"Chem Res Toxicol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/0731-7085(91)80036-9","volume":"9","author":"JH Beijnen","year":"1991","unstructured":"Beijnen JH, Meenhorst PL, van Gijn R, Fromme M, Rosing H, Underberg WJM (1991) HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients. J Pharm Biomed Anal 9:995?1002","journal-title":"J Pharm Biomed Anal"},{"key":"CR15","unstructured":"Beal SL, Sheiner LB (1998) NONMEM User?s Guide University of California at San Francisco: NONMEM Project Group"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO (1999) Xpose?an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51?64","journal-title":"Comput Methods Programs Biomed"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0277-5379(86)90067-2","volume":"22","author":"J Cummings","year":"1986","unstructured":"Cummings J, Milstead R, Cunningham D, Kaye S (1986) Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum. Eur J Cancer Clin Oncol 22:991?1001","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<517::AID-CNCR20>3.0.CO;2-0","volume":"78","author":"AM Levine","year":"1996","unstructured":"Levine AM, Tulpule A, Espina B, Boswell W, Buckley J, Rasheed S, Stain S, Parker J, Nathwani B, Gill PS (1996) Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Cancer 78:517?526","journal-title":"Cancer"},{"key":"CR19","first-page":"47","volume":"64","author":"RT Chlebowski","year":"1980","unstructured":"Chlebowski RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, Bateman JR (1980) Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64:47?51","journal-title":"Cancer Treat Rep"},{"key":"CR20","first-page":"193","volume":"5","author":"W Mattsson","year":"1982","unstructured":"Mattsson W, Borgstrom S, Landberg T (1982) A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer. Clin Ther 5:193?203","journal-title":"Clin Ther"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-99-6-745","volume":"99","author":"FM Torti","year":"1983","unstructured":"Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW Jr, Billingham ME (1983) Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 99:745?749","journal-title":"Ann Intern Med"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","volume":"15","author":"PA Speth","year":"1988","unstructured":"Speth PA, van Hoesel QG, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15?31","journal-title":"Clin Pharmacokinet"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.ejca.2003.12.026","volume":"40","author":"MA Rudek","year":"2004","unstructured":"Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD (2004) Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 40:1170?1178","journal-title":"Eur J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0900-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-004-0900-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0900-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:06:09Z","timestamp":1559023569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-004-0900-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,23]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1007\/s00280-004-0900-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,23]]}}}